

Kyle Parcella

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7589208/publications.pdf>

Version: 2024-02-01

7
papers

80
citations

1684188
5
h-index

1720034
7
g-index

7
all docs

7
docs citations

7
times ranked

111
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery of a Hepatitis C Virus NS5B Replicase Palm Site Allosteric Inhibitor (BMS-929075) Advanced to Phase 1 Clinical Studies. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 4369-4385.	6.4	26
2	Improving Metabolic Stability with Deuterium: The Discovery of BMT-052, a Pan-genotypic HCV NS5B Polymerase Inhibitor. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 771-774.	2.8	24
3	The discovery of a pan-genotypic, primer grip inhibitor of HCV NS5B polymerase. <i>MedChemComm</i> , 2017, 8, 796-806.	3.4	11
4	Discovery and Preclinical Profiling of GSK3839919, a Potent HIV-1 Allosteric Integrase Inhibitor. <i>ACS Medicinal Chemistry Letters</i> , 2022, 13, 972-980.	2.8	9
5	Discovery and initial optimization of alkoxyanthranilic acid derivatives as inhibitors of HCV NS5B polymerase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 295-298.	2.2	5
6	Scaffold modifications to the 4-(4,4-dimethylpiperidinyl) 2,6-dimethylpyridinyl class of HIV-1 allosteric integrase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2022, 67, 116833.	3.0	3
7	Structure-Property Basis for Solving Transporter-Mediated Efflux and Pan-Genotypic Inhibition in HCV NS5B Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 1217-1222.	2.8	2